Latigo Biotherapeutics launched an IPO that brought in $346 million earmarked for a non-opioid pain program progressing toward pivotal testing. The company also plans to allocate proceeds to additional pipeline work as it moves toward late-stage regulatory milestones. Alongside Latigo, BlossomHill Therapeutics debuted on the Nasdaq, raising new cash for cancer therapies designed around mutations not currently addressed by available treatments. Together, the two listings reflect investor focus on differentiated therapeutic mechanisms in pain and precision oncology. For biotech stakeholders, the deals matter less for their headline valuations and more for how quickly both companies can translate public funding into clinical execution—particularly as pivotal trials and biomarker strategies become the critical path for differentiation.